LivaNova (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.08), Fidelity Earnings reports. The company had revenue of $272.10 million during the quarter, compared to analysts’ expectations of $275.03 million. LivaNova had a positive return on equity of 9.24% and a negative net margin of 4.93%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $0.83 earnings per share. LivaNova updated its FY 2018 guidance to $3.50-3.70 EPS and its FY18 guidance to $3.50 to $3.70 EPS.
Shares of LIVN traded up $0.73 during midday trading on Thursday, hitting $112.72. 12,783 shares of the company traded hands, compared to its average volume of 454,043. LivaNova has a 52 week low of $72.30 and a 52 week high of $131.54. The company has a market capitalization of $5.26 billion, a PE ratio of 33.82, a price-to-earnings-growth ratio of 3.17 and a beta of 0.95. The company has a quick ratio of 1.08, a current ratio of 1.51 and a debt-to-equity ratio of 0.03.
In related news, insider Douglas John Manko sold 2,058 shares of the stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $121.61, for a total value of $250,273.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $121.58, for a total transaction of $121,580.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,058 shares of company stock valued at $963,033 in the last three months. Insiders own 0.41% of the company’s stock.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Article: What is the yield curve?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.